Macroscopic Hematuria Segment has the Largest Share of Type in the Middle East & Africa Hematuria Treatment Market during 2021–2028

According to our latest study on “Middle East & Africa Hematuria Treatment Market Forecast to 2028 – COVID-19 Impact and Analysis – by Type, Treatment, Indication, and End User,” the market is projected to reach US$ 46.8 million by 2028 from US$ 42.0 million in 2021; it is expected to grow at a CAGR of 1.5% from 2021 to 2028. The report highlights trends prevailing in the market, and the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the high prevalence of hematuria- associated indications, increasing awareness about treatment options and improving healthcare expenditure are factors propelling the hematuria treatment market. However, the undiagnosed cases of associated indications may hamper the growth of the Middle East & Africa hematuria treatment market in the forecast period.

In the MEA region, the number of patients hospitalized in intensive care units (ICU) is rising, as is the number of pharmaceuticals prescribed, creating many diagnostic and therapeutic problems for already overburdened healthcare systems. COVID-19 symptoms are mostly seen in the pulmonary system, but urogenital manifestations and/or consequences are given special attention. The risk of serious infection is higher in older patients with CKD, and AKI is linked to a high fatality rate. Thus, it was necessary to monitor the kidney function of patients with severe COVID-19, and CRRT for protecting kidney function and cytokine elimination for critically ill patients was critical to improving recovery. COVID-19 infection, on the other hand, appears to have ramifications for the urogenital tract. When treating COVID-19, urogenital organs should be considered.

Based on type, the Middle East & Africa hematuria treatment market is bifurcated into macroscopic hematuria, microscopic hematuria, idiopathic hematuria, and jogger’s hematuria. In 2021, the macroscopic hematuria segment is estimated to account for the largest market share. However, microscopic hematuria segment is estimated to register the highest CAGR during forecast period. Macroscopic hematuria is also known as gross hematuria. It is diagnosed by various methods such as blood tests, kidney biopsy, and others diagnosis techniques.

AstraZeneca, Bristol-Myers Squibb Company, F. HOFFMANN-LA ROCHE LTD., GlaxoSmithKline plc., Janssen Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc.,Sun Pharmaceutical Industries Ltd, and Boehringer Ingelheim International GmbH are among the leading companies in the Middle East & Africa hematuria treatment market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, AstraZeneca, in September 2021, the new plant will allow for late-stage development and early commercial supply, adopting state of the art process technology and digital innovation that is designed to meet the needs of the Company’s new medicines pipeline with speed and agility.

The market for hematuria treatment market is segmented into type, treatment, Indication, and end user. Based on type, the Middle East & Africa hematuria treatment market is segmented into macroscopic hematuria, microscopic hematuria, idiopathic hematuria, and jogger’s hematuria. Based on treatment, the hematuria treatment market is segmented drugs, therapies, and others. Based on indication, the hematuria treatment market is segmented into urinary tract infections, kidney stones, urethritis, blood cancer, bladder stones, prostate cancer, cystitis, trauma, vigorous exercise, polycystic kidney disease, endometriosis, and menstruation. Based on end user, the hematuria treatment market is segmented into hospitals, clinics, and Ambulatory Surgical Centers, and others. Geographically, the hematuria treatment market is segmented into Middle East & Africa (UAE, Saudi Arabia, South Africa, Rest of Middle East & Africa).

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com